Efficacy of Ciprofloxacin in Patients with Cystic Fibrosis

Abstract

Spanish

French

Twenty-five courses of oral ciprofloxacin were administered to 16 patients experiencing pulmonary exacerbations of cystic fibrosis in an open, uncontrolled trial of efficacy and tolerance. Patients were treated for 7–35 days and efficacy was evaluated based on changes in clinical score, white blood cell count, quantitative bacteriology of sputum, and pulmonary function tests. Most courses of therapy were associated with a positive response with changes in clinical score and forced expiratory volume in one second being statistically significant (p < 0.05). No side effects to ciprofloxacin were noted. Emergence of bacterial resistance to ciprofloxacin was rare. Ciprofloxacin appears to be effective in patients with cystic fibrosis who are experiencing pulmonary exacerbations associated with susceptible bacterial pathogens.

Get full access to this article

View all access options for this article.

References

Fass

. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother 1983; 24: 568–74.

Rudin

Norden

Shinners

. In vitro activity of ciprofloxacin against aerobic gram-negative bacteria. Antimicrob Agents Chemother 1984; 26: 597–8.

Hodson

Roberts

Butland

RJA

Smith

Batten

. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adult cystic fibrosis. Lancet 1987; 1: 235–7.

Kercsmar

Stern

Reed

Murdell

Blumer

. Ceftazidime in cystic fibrosis: Pharmacokinetics and therapeutic response. J Antimicrob Chemother 1983; 12 (suppl A): 289–95.

Gilardi

. Pseudomonas. In: Lennettee

, ed. Manual of clinical microbiology. Washington, DC: American Society for Microbiology, 1985: 350–72.

Bauer

Kirby

WMM

Sherris

Turck

. Antibiotic susceptibility testing by a standard single disc method. Am J Clin Pathol 1966; 45: 493–6.

National Committee for Clinical Laboratory Standards. Tentative standard: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-T. Villanova, PA, 1983.

Wientzen

Prestidge

Kramer

McCracken

Nelson

. Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy. Am J Dis Child 1980; 134: 1134–8.

Hyatt

Chipps

Kumor

Mellits

Lietman

Rosenstein

. A double-blind controlled trial of chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1981; 99: 307–11.

10.

Bosso

. Should pulmonary exacerbations of cystic fibrosis be treated with antibiotics? (editorial) Drug Intell Clin Pharm 1984; 18: 825–6.

11.

Scully

Nakatomi

Ores

Davidson

Neu

. Ciprofloxacin therapy in cystic fibrosis. Am J Med 1987; 82 (suppl 4A): 196–201.

12.

Shalit

Stutman

Marks

Chartrand

Hillman

. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am J Med 1987; 82 (suppl 4A): 189–95.

13.

Bosso

Black

Matsen

. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med 1987; 82 (suppl 4A): 180–4.